Evidence map›Paper›PMID 20483451›Full record

SynthesisLancet (London, England)2010

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Chronic Kidney Disease Prognosis Consortium, Kunihiro Matsushita, Marije van der Velde, Brad C Astor, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh, Ron T Gansevoort

3 registry-linked trialsOpen access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in Lancet (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 2,030 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,030citing papers in PubMed, 8 pooled it
124.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01792661 nacompletednot on this mapstarted 2012, after this paper: background citation

Navigating the Challenges of Chronic Kidney Disease

TypeinterventionalSponsorThe Cleveland ClinicRan2012 to 2015Enrolled209ConditionsChronic Kidney DiseaseArmsEnhanced MyChart, Patient Navigator, MyChart
NCT02917070 completednot on this mapstarted 2016, after this paper: background citation

The Importance of Parental Consanguinity and Family History of Kidney Disease in Turkish Adult Chronic Kidney Disease Population

Typeobservational_patient_registrySponsorIstanbul UniversityRan2016 to 2016Enrolled2,576ConditionsHereditary DiseasesArmsPatients
NCT06051812 active not recruitingnot on this mapstarted 2021, after this paper: background citation

A Prospective, Observational, Non-interventional, Single-center Study to Analyze the Relationship Between Proteinuria and Renal Perfusion in Renal Transplant Recipients

TypeobservationalSponsorUniversity of Erlangen-Nürnberg Medical SchoolRan2021 to 2026Enrolled25ConditionsPre-kidney Transplant, Living Donor Kidney Transplantation, Renal Perfusion, End Stage Renal Disease
3 · Its place in the literature

Who cites it

2,030 citing papers in PubMed, 8 syntheses or guidelines pooled it, 4,090 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pharmacotherapy for mild hypertension.The Cochrane database of systematic reviews · 2025
    Pooled it
  9. Trial
  10. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025 · on this map
    Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Type 1 diabetes and cardiovascular medicine.Cardiovascular diabetology. Endocrinology reports · 2026
    Review

1,970 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Chronic Kidney Disease Prognosis ConsortiumDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E Monument, Suite 2-630, Baltimore, MD 21287, USA.
Kunihiro Matsushita
Marije van der Velde
Brad C Astor
Mark Woodward
Andrew S Levey
Paul E de Jong
Josef Coresh
Ron T Gansevoort
Johns Hopkins University · USUniversity of Groningen · NLThe University of Sydney · AUTufts University · US

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
THE EPIDEMIOLOGY OF AGE-RELATED OCULAR DISEASEU10EY006594 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, RONALD · 1987 to 2018
$17.3M
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
CHS Events Follow-up StudyR01HL080295 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2009 to 2014
$6.3M
Predictors of Alheimers Disease in Mild Cognitive ImpairmentR01AG020098 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOPEZ, OSCAR L. · 2002 to 2011
$3.7M
MORTALITY FOLLOW-UP AND ANALYSES OF MEN IN THE MRFITR01HL068140 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEATON, JAMES DENNIS · 2001 to 2005
$2.6M
GENDER DIFFERENCES IN OSTEOPOROSISR01AG007181 · NIA · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BARRETT-CONNOR, ELIZABETH L · 1999 to 2002
$1.6M
CVD Predictors of Cognitive Function Trajectory over 20 YearsR01AG028507 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BARRETT-CONNOR, ELIZABETH L · 2007 to 2010
$1.2M
Hormonal trajectories in agingR01AG027058 · NIA · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, ANNE R · 2006 to 2009
$1.2M
Novel Risk Factors for Chronic Kidney DiseaseR01DK073217 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, RONALD · 2006 to 2008
$800k
Novel Cardiac Risk Factors &Endothelial Function in CKDK23DK067303 · NIDDK · TUFTS MEDICAL CENTER · PI MENON, VANDANA · 2004 to 2008
$781k
CARDIOVASCULAR RISK FACTORS--CHRONIC RENAL INSUFFICIENCYK23DK002904 · NIDDK · TUFTS MEDICAL CENTER · PI SARNAK, MARK J · 2000 to 2004
$672k
NEI NIH HHS U10 EY006594NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS N01 HC015103NHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01 HC035129NHLBI NIH HHS N01 HC045133NHLBI NIH HHS N01 HC055222NHLBI NIH HHS N01 HC075150NHLBI NIH HHS N01 HC085079NHLBI NIH HHS N01 HC085086NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL043232NHLBI NIH HHS R01 HL068140NHLBI NIH HHS R01 HL080295NIA NIH HHS R01 AG007181NIA NIH HHS R01 AG015928NIA NIH HHS R01 AG020098NIA NIH HHS R01 AG023629NIA NIH HHS R01 AG027058NIA NIH HHS R01 AG028507NIDDK NIH HHS K23 DK002904NIDDK NIH HHS K23 DK067303NIDDK NIH HHS R01 DK031801NIDDK NIH HHS R01 DK073217NIDDK NIH HHS U01 DK035073NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

backgroundSubstantial controversy surrounds the use of estimated glomerular filtration rate (eGFR) and albuminuria to define chronic kidney disease and assign its stages. We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality.

methodsIn this collaborative meta-analysis of general population cohorts, we pooled standardised data for all-cause and cardiovascular mortality from studies containing at least 1000 participants and baseline information about eGFR and urine albumin concentrations. Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause and cardiovascular mortality associated with eGFR and albuminuria, adjusted for potential confounders.

findingsThe analysis included 105,872 participants (730,577 person-years) from 14 studies with urine albumin-to-creatinine ratio (ACR) measurements and 1,128,310 participants (4,732,110 person-years) from seven studies with urine protein dipstick measurements. In studies with ACR measurements, risk of mortality was unrelated to eGFR between 75 mL/min/1.73 m(2) and 105 mL/min/1.73 m(2) and increased at lower eGFRs. Compared with eGFR 95 mL/min/1.73 m(2), adjusted HRs for all-cause mortality were 1.18 (95% CI 1.05-1.32) for eGFR 60 mL/min/1.73 m(2), 1.57 (1.39-1.78) for 45 mL/min/1.73 m(2), and 3.14 (2.39-4.13) for 15 mL/min/1.73 m(2). ACR was associated with risk of mortality linearly on the log-log scale without threshold effects. Compared with ACR 0.6 mg/mmol, adjusted HRs for all-cause mortality were 1.20 (1.15-1.26) for ACR 1.1 mg/mmol, 1.63 (1.50-1.77) for 3.4 mg/mmol, and 2.22 (1.97-2.51) for 33.9 mg/mmol. eGFR and ACR were multiplicatively associated with risk of mortality without evidence of interaction. Similar findings were recorded for cardiovascular mortality and in studies with dipstick measurements.

interpretationeGFR less than 60 mL/min/1.73 m(2) and ACR 1.1 mg/mmol (10 mg/g) or more are independent predictors of mortality risk in the general population. This study provides quantitative data for use of both kidney measures for risk assessment and definition and staging of chronic kidney disease.

fundingKidney Disease: Improving Global Outcomes (KDIGO), US National Kidney Foundation, and Dutch Kidney Foundation.

Indexed as

AlbuminuriaGlomerular Filtration RateMortalityAgedCardiovascular DiseasesChronic DiseaseCreatinineFemaleHumansKidney DiseasesMaleMiddle AgedProportional Hazards ModelsCreatinine

Identifiers

PMID20483451
PMCPMC3993088
OpenAlexW1570583414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.